A role for RIO kinases in the crosshair of cancer research and therapy
Biochim Biophys Acta Rev Cancer. 2024 Apr 9;1879(3):189100. doi: 10.1016/j.bbcan.2024.189100. Online ahead of print.ABSTRACTRIO (right open reading frame) family of kinases including RIOK1, RIOK2 and RIOK3 are known for their role in the ribosomal biogenesis. Dysfunction of RIO kinases have been implicated in malignancies, including acute myeloid leukemia, glioma, breast, colorectal, lung and prostatic adenocarcinoma suggesting RIO kinases as potential targets in cancer. In vitro, in vivo and clinical studies have demonstrated that RIO kinases are overexpressed in various types of cancers suggesting important roles in tumo...
Source: Biochimica et Biophysica Acta - April 11, 2024 Category: Biochemistry Authors: Morteza Ghandadi Albert Dobi Sanjay V Malhotra Source Type: research
Construction and validation of key genes-related prognosis model in children with acute myeloid leukaemia
CONCLUSION: A prognosis-related gene model of AML was successfully constructed, and the expression levels of the model genes varied with AML stage.PMID:38600718 | DOI:10.1111/ijlh.14272 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - April 11, 2024 Category: Hematology Authors: Fan Huang Chuan Ming Yuqian Jiang Chenli Li Cheng Tan Source Type: research
FLT-3 mutation maybe an inferior predictor of daratumumab therapy in acute myeloid leukemia patients relapsed after allogeneic stem cell transplantation
Int J Lab Hematol. 2024 Apr 10. doi: 10.1111/ijlh.14275. Online ahead of print.NO ABSTRACTPMID:38600651 | DOI:10.1111/ijlh.14275 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - April 11, 2024 Category: Hematology Authors: Song Xue Wenqiu Huang Yongping Zhang Fuhong Liu Qi Hao Jiajun Hu Lei Yuan Jingbo Wang Source Type: research
CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF- β signaling driving myelofibrosis
AbstractThe classicalBCR::ABL1-negative myeloproliferative neoplasms (MPN) form a group of bone marrow (BM) diseases with the potential to progress to acute myeloid leukemia or develop marrow fibrosis and subsequent BM failure. The mechanism by which BM fibrosis develops and the factors that drive stromal activation and fibrosis are not well understood. Cellular Communication Network 2 (CCN2), also known as CTGF (Connective Tissue Growth Factor), is a profibrotic matricellular protein functioning as an important driver and biomarker of fibrosis in a wide range of diseases outside the marrow. CCN2 can promote fibrosis direc...
Source: Virchows Archiv - April 11, 2024 Category: Pathology Source Type: research
Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)
CONCLUSIONS: We report epidemiological data from a large international cohort of children and adolescents with LyP. Overall the prognosis of the disease is good, with excellent survival rates for all patients. Due to increased risk of associated HM, a long-term follow-up should be recommended for LyP patients.PMID:38595050 | DOI:10.1093/bjd/ljae150 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Ma ël Blanchard Marie-Anne Morren Anne-Marie Busschots Esther Hauben Silvia Alberti-Violetti Emilio Berti Gianluca Avallone Gianluca Tavoletti Michele Panzone Pietro Quaglino Cristiana Colonna Rutger C Melchers Maarten H Vermeer Robert Gniadecki Christin Source Type: research
B7-H3 in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target
Chin Med J (Engl). 2024 Apr 9. doi: 10.1097/CM9.0000000000003099. Online ahead of print.ABSTRACTB7-H3 (CD276), an immune checkpoint protein of the B7 family, exhibits significant upregulation in solid tumors and hematologic malignancies, exerting a crucial role in their pathophysiology. The distinct differential expression of B7-H3 between tumors and normal tissues and its multifaceted involvement in tumor pathogenesis position it as a promising therapeutic target for tumors. In the context of acute myeloid leukemia (AML), B7-H3 is prominently overexpressed and closely associated with unfavorable prognoses, yet it has rema...
Source: Chinese Medical Journal - April 10, 2024 Category: General Medicine Authors: Xiao Tan Xiangyu Zhao Source Type: research
Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)
CONCLUSIONS: We report epidemiological data from a large international cohort of children and adolescents with LyP. Overall the prognosis of the disease is good, with excellent survival rates for all patients. Due to increased risk of associated HM, a long-term follow-up should be recommended for LyP patients.PMID:38595050 | DOI:10.1093/bjd/ljae150 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Ma ël Blanchard Marie-Anne Morren Anne-Marie Busschots Esther Hauben Silvia Alberti-Violetti Emilio Berti Gianluca Avallone Gianluca Tavoletti Michele Panzone Pietro Quaglino Cristiana Colonna Rutger C Melchers Maarten H Vermeer Robert Gniadecki Christin Source Type: research
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Leukemia, Published online: 10 April 2024; doi:10.1038/s41375-024-02246-2Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia (Source: Leukemia)
Source: Leukemia - April 10, 2024 Category: Hematology Authors: Harry Fruchtman Zachary M. Avigan Julian A. Waksal Nicole Brennan John O. Mascarenhas Source Type: research
Discovery of novel co-degradation CK1 α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
In this study, we designed and synthesized a series of novel PROTACs to reactivate p53 via the co-degradation of CK1α and CDK7/9 proteins. Bioactivity studies showed that the selected PROTAC 13i exhibited potency antiproliferative activity in MV4-11 (IC50 = 0.096 ± 0.012 μM) and MOLM-13 (IC50 = 0.072 ± 0.014 μM) cells, and induced apoptosis of MV4-11 cells. Western-blot analysis showed that PROTAC 13i triple CK1α and CDK7/9 protein degradation resulted in the significantly increased expression of p53. At the same time, the transcriptional repression due to the degradation significantly reduced downstream gene express...
Source: Bioorganic Chemistry - April 9, 2024 Category: Chemistry Authors: Kai Wang Meixu Jiang Huimin Liu Chen Meng Mengyuan Li Haibin Lu Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
Discovery of novel co-degradation CK1 α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
In this study, we designed and synthesized a series of novel PROTACs to reactivate p53 via the co-degradation of CK1α and CDK7/9 proteins. Bioactivity studies showed that the selected PROTAC 13i exhibited potency antiproliferative activity in MV4-11 (IC50 = 0.096 ± 0.012 μM) and MOLM-13 (IC50 = 0.072 ± 0.014 μM) cells, and induced apoptosis of MV4-11 cells. Western-blot analysis showed that PROTAC 13i triple CK1α and CDK7/9 protein degradation resulted in the significantly increased expression of p53. At the same time, the transcriptional repression due to the degradation significantly reduced downstream gene express...
Source: Bioorganic Chemistry - April 9, 2024 Category: Chemistry Authors: Kai Wang Meixu Jiang Huimin Liu Chen Meng Mengyuan Li Haibin Lu Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy
ConclusionsIn this study, we observed treatment persistent MR leukemic subclones and their phenotypic changes during the treatment process of R/R AML patients. This underscores the importance of preemptive inhibition of clonal promiscuity in R/R AML, proposing a practical method for monitoring AML MR subclones. (Source: Cancer Medicine)
Source: Cancer Medicine - April 9, 2024 Category: Cancer & Oncology Authors: Dongchan Kim,
Sheehyun Kim,
Hyojin Song,
Daehyeon Gwak,
Suji Min,
Ja Min Byun,
Youngil Koh,
Junshik Hong,
Sung ‐Soo Yoon,
Hongseok Yun,
Dong‐Yeop Shin Tags: BRIEF COMMUNICATION Source Type: research
